Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma.

Louisa SternConstantin SchmidtLorenz KocheiseVincent JoergChristian CasarAurélie WalterJoost P H DrenthMaria PappNikolaos K GatselisKalliopi ZachouMatthias PinterBernhard ScheinerArndt VogelMartha M KirsteinFabian FinkelmeierOliver WaidmannArndt WeinmannPiotr MilkiewiczDouglas ThorburnNeil HallidayAna LleoSamuel HuberGeorge N DalekosAnsgar W LohseHenning WegeJohann von FeldenKornelius Schulze

Published in: Annals of hepatology (2024)

In summary, this study demonstrates comparable mOS for AILD-HCC patients undergoing local and systemic treatments, with better tolerability than HCC of other causes. TKIs remain important therapeutic options for AILD-HCC patients, particularly given their exclusion from recent immunotherapy trials.

Keyphrases

patients undergoing
end stage renal disease
newly diagnosed
peritoneal dialysis
prognostic factors
palliative care
open label
randomized controlled trial
room temperature
smoking cessation
double blind